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Summary. In recent years, evidence from various animal ex- 
periments has accumulated that emphasizes the role of endo- 
thelin-1 in the pathophysiology of several cardiovascular dis- 
eases, including congestive heart failure. The recent advent 
of potent antagonists of this system now allows the assess- 
ment of the involvement of endothelin-1 in the maintenance 
of vascular tone in animals and humans. We report hemody- 
namic data from two trails in patients with chronic severe 
congestive heart failure (i.e., reduced left ventricular ejec- 
tion fraction of <30%, elevated resting pulmonary capillary 
wedged pressure >15 mmHg, and/or reduced cardiac index 
of 2.5 L/min/m 2 or less) who were treated with the mixed 
endothelin-type A and type B-receptor antagonist bosentan. 
In the first study, the acute effect of bosentan (300 mg, intra- 
venous) on hemodynamics and neurohormones was investi- 
gated. Bosentan was well tolerated and significantly im- 
proved impaired hemodynamics due to systemic and venous 
vasodilation. In the second trial, bosentan was given orally 
(0.5 g bid) for 14 days, in addition to conventional triple treat- 
ment for congestive heart failure, including digitalis, angio- 
tensin-converting enzyme inhibitors, and diuretics. Cardiac 
hemodynamics were monitored during the first 24 hours of 
treatment, and measurements were repeated during the last 
day of bosentan therapy. Bosentan was well tolerated in 
these patients as well, and hemodynamic measures were com- 
patible with an additional effect of bosentan after 2 weeks. 
However, there was a slight increase in heart rate as well. 
Our result underline the importance of endogenously gener- 
ated endothelin-1 in congestive heart failure and suggest a 
potential benefit of endothelin antagonism in such patients. 
However, long-term studies are needed to establish whether 
chronic endothelin antagonism has beneficial clinical effects 
and is capable of improving survival and/or symptoms in se- 
vere heart failure patients who remain symptomatic despite 
standard triple therapy. 
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and vasoconstrictor mediators [1-3]. While the func- 
tion of endothelium-derived relaxing factor, presumed 
to be nitric oxide [4], in the regulation of arteriolar 
tone in normal subjects [5,6] and in many diseases, 
among them chronic heart failure [7], hypertension [8], 
hypercholesterolemia [9], and smokers [6], is well es- 
tablished the role of the vasoconstrictor peptide ndo- 
thelin-1 [2] is much less clear. Evidence is accumulating 
that endothelin-1 is abluminally released and is di- 
rected towards the vessel walls, where it increases vas- 
cular muscle tone, acting as an autocrine or paracrine 
stimulator. The pharmacological effects of infused en- 
dothelin-1 are well recognized [10]. Besides being a 
functionally important vasoconstrictor, it is involved in 
the regulation of electrolyte balance and modulates se- 
cretion of other hormonal systems that regulate mito- 
genesis and grow-related metabolism [11-13]. 
Increased plasma concentrations of this potent va- 
soconstrictor have been described in many circum- 
stances, such as renal failure [14], severe hyperten- 
sion [15], pulmonary hypertension [16], coronary 
endothelial dysfunction [17], coronary vasospasm [18], 
and chronic heart failure [19,20] and may be related 
to a poor prognosis after myocardial infarction [21]. 
Similarly, in severe heart failure, high levels of 
plasma big endothelin-1, the precursor of endo- 
thelin-1, are associated with low survival and seem 
to predict 1-year mortality better than hemodynamic 
variables or neurohormonal prognostic markers of 
congestive heart failure [22]. However, these findings 
obviously do not prove an involvement ofendothelin-1 
in the pathophysiology of these conditions. Rather, 
they might reflect reduced renal and/or pulmonary 
clearance or endothelial damage with increased pep- 
tide release. Likewise, the finding that endothelin-1 
Intense laboratory and clinical research over the last 
15 years has unequivocably documented that the endo- 
thelium is one of the major sources of substances in- 
volved in the regulation of vascular muscle tone and, 
thus, vascular resistance by releasing both vasodilator 
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infusions resulting in pathophysiological blood concen- 
trations caused profound vasoconstriction in animals 
[23] and, similarly, following big endothelin-1 infusion 
in humans [24], is suggestive for a role of endothelin-1 
in many diseases associated with high circulating en- 
dothelin-1 levels but does not provide clearcut proof. 
The recent development of specific endothelin- 
receptor antagonists [25] now provides the means to 
clarify the role of endothelin-1 in the physiological nd 
pathophysiological regulation of vascular tone in hu- 
mans. Importantly, it was shown that administration 
of an endothelin-type A receptor antagonist, BQ 123, 
caused profound forearm vasodilation when infused 
directly into the brachial arteries of normal volunteers 
[26], but the endothelin-receptor antagonist bosentan 
did not have hemodynamic effect in normal, anesthe- 
tized dogs [27]. Because patients with heart failure 
often have elevated levels of plasma endothelin-1, we 
decided to use one of these ndothelin-receptor antag- 
onists, bosentan, in such patients, assessing changes 
of systemic hemodynamics as a means to further eluci- 
date the importance ofthis system in the maintenance 
of increased vascular tone that characterizes this con- 
dition. In addition, possible links between this endo- 
thelial regulator of vascular tone and the renin- 
angiotensin-aldosterone system will be discussed. 
Endothelin-1, its Receptors, 
and Bosentan 
Endothelin-1 is a 21-amino acid peptide with potent 
and sustained vasoconstrictor p operties. It is con- 
verted from the precursor plasma big endothelin-1 by 
an inhibitable metalloprothease. To date, two endo- 
thelin receptor subtypes have been identified, the en- 
dothelin-type A (ETA) and type B (ETs) receptors. 
While the ET A receptor is predominantly involved in 
endothelin-l-mediated vasoconstriction, the ETB re- 
ceptors might play a dual role, that is, induce vasocon- 
striction in some tissues [28] and vasodilatation in cer- 
tain other tissues [29]. Bosentan is a competitive, 
selective, and mixed endothelin receptor antagonist 
that specifically blocks both ET A and ET B receptors 
sites [25] and is orally active. Simultaneous systemic 
blockade of both receptor types was judged to be of 
advantage when examining the effect of acute and 
short-term inhibition of the hemodynamic and hu- 
moral consequences caused by the increased endo- 
thelin-1 levels. 
Acute Hemodynamic Effects of 
Bosentan in Severe Chronic 
Heart Failure 
Patients 
Two female and 22 male patients (35-70 years, mean 
51.9 +_ 10 years) with congestive heart failure of more 
than 3 months duration and dyspnea ccording to 
NYHA class III were studied [30]. All patients had a 
left ventricular ejection fraction of <30% (mean 23.2 
-+ 4.4%) and pulmonary artery wedge pressure was 
>15 mmHg and/or cardiac index at rest reduced (<2.5 
1/min/m2). 
All patients were clinically stable. Angiotensin- 
converting enzyme inhibitors were discontinued for 
four plasma half-lives prior to study for safety reasons 
because this was the first administration f this com- 
pound in such patients. Other medications were with- 
held on the morning of the study, with the exception 
of antiarrhythmic drugs (n = 4). 
Methods 
Systemic hemodynamics were measured invasively 
using standard techniques, using flow-guided ther- 
modilution catheters for the measurement of right 
sided cardiac and pulmonary artery pressures and car- 
diac output. Blood pressure was measured irectly 
from the radial or brachial artery and heart rate from 
the electrocardiogram. 
Patients were randomized to receive double-blind 
placebo or bosentan. Treatment was started with in- 
travenous infusion of 100 mg of bosentan or matching 
placebo (0.9% saline) over 15 minutes. Sixty minutes 
after starting the first infusion, an additional 200 mg 
of bosentan or placebo was infused in an identical man- 
ner. The cumulative dosage of 300 mg of bosentan 
infusion was assumed to reach plasma concentrations 
that were comparable with those obtained in animals 
studies with experimental congestive heart failure in 
which endothelin antagonism was shown to be effec- 
tive. As an additional safety measure, the infusions 
were performed in two dose steps, separated by a 
washout period sufficient o allow for hemodynamic 
"adjustment." 
Hemodynamic measurements were obtained 5, 20, 
40, and 60 minutes after the onset of each bosentan 
infusion. Blood for hormone determination (endo- 
thelin-1, big endothelin-1, noradrenaline, plasma re- 
nin activity) was drawn immediately before bosentan 
infusion and 60 minutes after the first and second infu- 
sions, respectively. Differences in hemodynamic and 
hormonal measurements in the two study groups were 
compared using analysis of variance for repeated mea- 
sures. Finally, plasma concentrations of bosentan 
were determined. Mean maximum plasma concentra- 
tions of bosentan reached 10 _+ 3 }xg/mL 20 minutes 
after the first and 32 _+ 8 ~g/mL 20 minutes after the 
second infusion, respectively. 
Results 
Baseline hemodynamic values were not significantly 
different in both study groups. Expectedly, though, 
plasma endothelin-1 levels were elevated in these pa- 
tients [36.4 -+ 13.7 (SD) pg/ml; normal <15 pg/ml] 
and, as described earlier [31], were directly correlated 
with mean pulmonary artery, pulmonary artery 
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Fig. 1. Relationships between baseline plasma endothelin-1 
concentrations and the extent of pulmonary hypertension, car- 
diac filling pressures, and cardiac index in patients with 
chronic heart failure. The correlations indicate that higher 
plasma endothelin-1 concentrations are associated with a 
greater degree of pulmonary hypertension, more severely ele- 
vated right- and left-sided cardiac filling pressures, and lower 
cardiac index. 
wedge pressure, and right atrial pressures, and indi- 
rectly with cardiac index (Fig. 1). This finding indi- 
cates that the severity of hemodynamic impairment is 
related to the activation of this system, as measured 
by endothelin-1 levels in blood, but it has to be kept 
in mind that the main action of this system occurs 
presumably in an autocrine/paracrine fashion in the 
vessel wall [32]. 
The hemodynamic effects of randomized adminis- 
tration of either placebo r bosentan are shown in Fig- 
ures 2 and 3, which depict absolute changes from base- 
line measurements. Placebo infusion did not induce 
significant hemodynamic changes throughout he 
study period, attesting to the hemodynamic stability 
of the patients and the feasibility of the experimental 
procedure. In contrast, bosentan significantly reduced 
mean arterial and pulmonary artery pressure, and 
right atrial and pulmonary artery wedge pressures, 
and increased cardiac and stroke volume index, while 
heart rate did not change. Consequently, calculated 
systemic vascular esistance decreased significantly, 
as did pulmonary vascular esistance. As illustrated 
in Figures 2 and 3, an initial marked effect of bosentan 
was seen only 20 minutes after the first (100-mg) infu- 
sion, and this effect persisted for up to 60 minutes. 
Infusion of the second dose in addition to the first 
dose appeared to have an additional effect, at least on 
measured pressures, but it is difficult if not impossible 
to say whether this effect is due to the additional dose 
and, possibly, more complete endothelin-receptor 
blockade or whether it represents he continued and 
increasing effect of the first bosentan dose. 
Plasma endothelin-1 levels were comparably ele- 
vated in both study groups at baseline and increased 
significantly in bosentan-treated patients (from 38.9 
_+ 11.4 to 89.6 +- 27.1 pg/ml, p < 0.01) and remained 
unchanged in placebo-treated patients. Plasma big en- 
dothelin-1, norepinephrine, angiotensin II, and renin 
activity remained unchanged in both groups. None of 
the measured hormones was significantly correlated 
with hemodynamic changes. 
Limitations and potential implications 
Taken together, the study for the first time provides 
evidence that acute systemic treatment with an endo- 
thelin receptor antagonist results in significant hemo- 
dynamic hanges in patients with chronic heart failure 
and elevated circulating endothelin-1 levels, demon- 
strating that this endothelial vasoconstrictor system 
plays a role in the circulatory pathophysiology in these 
patients. Therefore, interference with this system by 
either specific receptor antagonists or with endo- 
thelin-1 converting enz~ae inhibitors may not only 
prove useful for the further delineation of this sys- 
tem's role in circulatory physiology and pathophysiol- 
ogy, but may lead to a new therapeutic approach. The 
hemodynamic profile of systemic, venous, and pulmo- 
nary arterial vasodilation and unchanged heart rate, 
as seen in this study, appears to be compatible, at 
least on theoretical grounds, with a beneficial role of 
chronic endothelin-1 antagonism in patients with 
heart failure. However, a number of points need 
comment. 
The present study cannot answer whether blockade 
of circulating endothelin-1 effects or paracrine/auto- 
crine effects induced by abluminally released endo- 
thelin-1 accounts for the observed hemodynamic 
changes. Both explanations appear possible because 
endothelin-1 infusions resulting in concentrations of 
twice the normal range had pronounced hemodynamic 
and antinatriuretic effects in animals [23]. Thus, the 
endothelin-1 system might prove to play a dual role 
in the control of vascular function by both local tissue 
and circulatory components, the relative importance 
of which will have to be determined. 
Plasma endothelin-1 levels, but not those of its pre- 
cursor big endothelin-1, increased more than twofold 
after bosentan, a finding similar to that seen after 
acute administration in dogs [27] or chronic oral ther- 
apy in mineralocorticoid-induced hypertension i  rats 
[33]. We cannot readily explain this phenomenon, but 
displacement of endothelin-1 from its receptor sites 
or a decreased clearance of endothelin-1 due to ET B 
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Fig. 2. Changes of arterial, pulmonary artery, pulmonary artery wedge, and right atrial pressures in patients with chronic heart 
failure given intravenous placebo r the endothelin-receptor antagonist bosentan. Placebo (squares) did not produce significant he- 
modynamic effects. In contrast, bosentan (circles) significantly lowered all measured pressures (** p < 0.01 by repeated-measures 
ANOVA). The greater portion of the response was seen with the lower bosentan dose [100 mg iv (open circles)], but the higher dose 
[(200 mg iv (closed circles)] seemed to have an additional effect. 
receptor blockade appears possible [34]. Increased 
synthesis ubsequent to interruption of a negative 
feedback mechanism also cannot be excluded, but big 
endothelin-1 did not increase, rendering this explana- 
tion unlikely. Increased conversion of big endothelin-1 
into endothelin-1 might also explain the finding, but a 
reduction of big endothelin-1 would then be expected. 
Clearly, more data are needed to assess the signifi- 
cance and underlying mechanisms ofthis finding. 
Exogenous endothelin-1 has heterogeneous vascu- 
lar effects, with a greater enal than coronary action 
in animals [23] and a doubling of renal vascular resis- 
tance as compared with an increase of mean blood 
pressure of only approximately 25% as found in hu- 
mans when big endothelin-1 was infused [24]. The 
measurement of systemic hemodynamic parameters, 
as in this study, can only give an integrated view of 
the possibly different responses of various vascular 
beds, and it remains to be seen whether endothelin 
antagonism in humans also has more marked effects 
in some vascular beds as compared with others. Thus, 
it will be of importance to see whether endothelin-1 
antagonism would also influence ndothelin-l-induced 
antinatriuresis [23], a phenomenon fgreat potential 
importance, particularly in chronic heart failure. 
The results from this acute hemodynamic study 
certainly do not indicate either beneficial hemody- 
namic effects during chronic therapy or improvement 
of symptoms, uch as increased exercise tolerance or 
reduced yspnea. So far, we even do not know which 
patients might respond acutely to this kind of therapy. 
Animal data suggest hat bosentan has little if any 
effect in rats with mild degrees of heart failure and 
that endothelin-1 antagonism is increasingly effective 
when heart failure becomes more severe and plasma 
endothelin-1 levels are elevated [35]. 
Plasma endothelin concentrations also increase in 
patients with more severe degrees of heart failure 
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Fig. 3. Changes of cardiac and stroke volume index, and of systemic and pulmonary vascular esistance, in patients with chronic 
heart failure given intravenous placebo r the endothelin-receptor antagonist bosentan. Placebo (squares) did not produce signifi- 
cant hemodynamic effects. In contrast, bosentan (circles) significantly increased cardiac and stroke volume index and lowered sys- 
tematic and pulmonary vascular esistance (** p < 0.01 by repeated-measures ANOVA). The greater portion of the response was 
seen with the lower bosentan dose [100 mg iv (open circles)], while the effect of the higher dose [(200 mg iv (closed circles)] ap- 
peared to be less consistent on these parameters as compared with its effects on pressure measurements. 
[20], and our results in patients with moderate to se- 
vere heart failure confirm previous findings of rela- 
tionships between plasma endothelin-1 levels and the 
extent of pulmonary hypertension, left ventricular 
filling pressure, and indices of systolic dysfunction, for 
example, cardiac output or left ventricular ejection 
fraction [19,20]. Thus, patients with more severe 
heart failure and elevated plasma endothelin-1 levels, 
as in this study might, on theoretical grounds, re- 
spond better to endothelin receptor antagonist ther- 
apy than patients with less hemodynamic impairment. 
We did not find a relationship between either endo- 
thelin-1 or big endothelin-1 plasma concentrations and 
hemodynamic changes after bosentan. However, the 
number of patients was too small to ascertain the pre- 
dictive value of circulating endothelin-1 and big endo- 
thelin-1 levels with respect o hemodynamic effects 
after blockade of its vascular effects. 
Hemodynamic Effects of Short-Term 
Oral Endothelin-Receptor 
Antagonist Therapy 
Rationale and study patients 
Studies using a rat model of chronic heart failure have 
shown that the effect of bosentan was additive to that 
of an angiotensin-converting e zyme inhibitor [35]. 
For safety reasons, angiotensin-converting e zyme 
inhibitors were discontinued in the acute study of bo- 
sentan, and, therefore, no conclusions could be drawn 
regarding the safety and possible additional hemody- 
namic effects of combined angiotensin-converting e - 
zyme inhibitor and endothelin-receptor antagonist 
therapy in patients with heart failure. Because addi- 
tional effects might be of benefit in a number of pa- 
tients who remain symptomatic on angiotensin- 
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converting enzyme inhibitors, we performed a pilot 
trial to assess both the safety and the hemodynamic 
effects of oral bosentan i  six men with chronic heart 
failure and dyspnea, NYHA class III, despite treat- 
ment with an angiotensin-converting e zyme inhibi- 
tor, digoxin, and diuretics. All patients had a left ven- 
tricular ejection fraction of <30% and pulmonary 
artery wedge pressure was > 15 mmHg in the morn- 
ing before taking their medications. 
Study design and methods 
Patients were studied hemodynamically twice 14 days 
apart using the same techniques as described earlier. 
On the first study day, 500 mg of bosentan was added 
in the morning and in the evening to the regular ther- 
apy, and hemodynamic measurements were obtained 
over 24 hours following the morning dose. Patients 
were then discharged on their regular therapy, to 
which bosentan 500 mg bid orally was added in an 
open fashion, and patients were restudied inan identi- 
cal manner 14 days later. Statistical nalysis was per- 
formed comparing hemodynamics at days 1 and 14 us- 
ing analysis of variance for repeated measures. 
Results 
Bosentan added to the patients' established therapy 
with diuretics, digoxin, and an angiotensin-converting 
enzyme inhibitor was well tolerated, and there were 
no untoward biochemical effects in serum electrolytes, 
creatinine, or liver enzymes. The main hemodynamic 
findings are depicted in Figure 4. When interpreting 
the results from this study, it is important to recall 
that due to the study design and the nature of the 
study being primarily a safety study, no conclusions 
can be drawn about the additional hemodynamic ef- 
fects of bosentan on the first study day. It is evident, 
however, that therapy reduced systemic vascular re- 
sistance and blood pressure, and the cardiac index in- 
creased. Changes in mean blood pressure were identi- 
cal during day 14 [mean difference throughout all 
measurements, 95% CI, -2.6 (0.35 to -5.5) mmI-Ig], 
but systemic vascular resistance was lower at day 14 
[mean decrease -232 ( - 122 to -342) dynes ec/cmS]. 
Cardiac index was increased [mean increase 0.35 (0.60 
to -0.10) 1/min/m2], but there was also an increase 
in heart rate [mean increase 6.5 (2.7 to 10.2) beats/ 
min]. Stroke volume was numerically higher through- 
out day 14 as compared with day 1 [mean increase 2.6 
(6.3 to -2.1) ml/m2], but this effect was not signifi- 
cant, as were changes observed for right atrial, pul- 
monary artery, or pulmonary capillary wedge pres- 
sures. 
Conclusions 
The conclusions that can be drawn from this study are 
obviously limited. However, it is important to note 
that additional therapy with bosentan was well toler- 
ated, and there was no symptomatic hypotension. The 
difference in hemodynamic parameters after 14 days 
of oral therapy would be compatible with a greater 
chronic than acute effect, but results from placebo- 
controlled trials will have to be awaited to clarify this 
issue. The study also cannot answer the question of 
what would constitute an appropriate dose. There is 
no way, thus far, to test the completeness of receptor 
blockade of this paracrine/autocrine system, and dose 
finding will have to rely on surrogate ndpoints, for 
example, hemodynamic changes or improvement of
exercise tolerance time. 
It is also worthy to note that heart rate was higher 
during day 14. This finding, which could indicate sym- 
pathetic activation due to arterial vasodilation and 
baroreceptor stimulation, differs from the lack of 
heart-rate ffects of acute bosentan administration 
[30]. Interestingly, the pattern of heart rate through- 
out both study days appeared to be similar, but it is 
obvious that the important issue regarding possible 
sympathetic activation during sustained endothelin- 
receptor antagonist therapy clearly needs further 
study. 
Effects Beyond Hemodynamic 
Benefit? 
The preliminary data obtained in patients with heart 
failure thus far seem to be encouraging enough to fur- 
ther pursue studies of endothelin-receptor antago- 
nists, particularly in patients not adequately treated 
with angiotensin-converting e zyme inhibitors. How- 
ever, it will also be of importance to see whether ef- 
fects other than those related to the regulation of vas- 
cular tone can be demonstrated by pharmacological 
interference with this system. 
Endothelin-1 has been shown to exert powerful mi- 
togenic effects, either directly or indirectly, in a vari- 
ety of cells, including cardiac myocytes [12,36], vascu- 
lar smooth muscle cells [11], mesangial cells [37], and 
cardiac fibroblasts [38]. Interestingly, endothelin-1 
seems to be involved in the mediation of the mitogenic 
effects of angiotensin II, thus pointing to a potentially 
important interaction between these two systems in 
chronic heart failure. Both endothelin-1 and angioten- 
sin II significantly stimulated [~H]-thymidine incorpo- 
ration into cardiac fibroblasts, whose effects were 
dose-dependently inhibited by an ETA receptor antag- 
onist (BQ123) [38], and angiotensin II-mediated vas- 
cular smooth muscle cell growth can be partly ex- 
plained by angiotensin II-induced endothelin-1 
production [39]. Also, in cultured rat cardiomyocytes, 
angiotensin II upregulated the cardiac endothelin-1 
gene in the same manner as did the immediate-early 
protooncogenes, and the late induction of the ET B re- 
ceptor, mainly via the cardiac angiotensin II type I 
receptor, is compatible with an involvement ofendog- 
enous endothelin-1 in angiotensin II-induced cardiac 
hypertrophy [40]. Angiotensin II also upregulates 
ET A receptors in human vascular smooth muscle cells, 
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Fig. 4. Changes in mean blood pressure, heart rate, cardiac index, and systemic vascular esistance on the first day of combined 
therapy with diuretics, digoxin, angiotensin-converting e zyme inhibitors, and the endothelin-receptor antagonist bosentan (open 
circles) and on the 14th day of combined therapy (closed circles). Bosentan 500 mg bid was given together with the other drugs 
in the morning and 12 hours later. ** p < 0.01 by profile analysis of repeated measurements. 
providing further evidence for a link between the re- 
nin-angiotensin a d the endothelin systems [41]. Dif- 
ferences in the release of endothelin-1 following endo- 
thelial angiotensin II type I receptor stimulation may 
also be responsible for the heterogeneity n vascular 
smooth muscle responsiveness to angiotensin II in dif- 
ferent vascular beds [42]. 
Endothelin-1 also seems to interact with the renin- 
angiotensin system and sympathetic nervous ystem. 
Thus, endothelin-1 stimulated the conversion of angio- 
tensin I to angiotensin II in cultured pulmonary ar- 
tery endothelial cells, thereby possibly indirectly reg- 
ulating vascular tone [43], and subpressor doses of 
endothelin-1 potentiated the vasoconstrictor response 
to norepinephrine in vitro [44]. Finally, angiotensin- 
converting enzyme inhibitors reduced the stimulated 
release of endothelin-1 from human endothelial cells 
in culture, presumably via potentiation of autacoid 
formation from the cells, thereby pointing to the pos- 
sibility that angiotensin-converting enzyme inhibitors 
may exert part of their hemodynamic and antiprolifer- 
ative effects via reduction of endothelin-1 production/ 
release and/or production of bradykinin and endothe- 
lium-derived nitric oxide [45]. 
Although the information regarding interactions 
between the renin-angiotensin and the endothelin sys- 
tems so far is almost entirely based upon in vitro ex- 
periments and deductions from such experiments o
the situation in humans in vivo have to be made with 
caution, it is interesting to speculate that combined 
blockade of both systems may be associated with 
many potentially beneficial cellular effects that clearly 
go beyond the hemodynamic effects that we are in the 
process of unraveling at present. 
Future of Endothelin Receptor 
Blockade 
A direct comparison of the effects of ETA-selective 
and mixed ET A and ET B receptor antagonists will be 
needed to determine the importance of ET s receptor 
blockade in humans. This might be of particular rele- 
vance in congestive heart failure, where vasoconstric- 
tion through the vascular smooth muscle ET-B- 
receptor mechanism seems to be enhanced [46]. 
Finally, the role of downregulation r upregulation of
the ETA and/or ET B receptors seen in association with 
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elevated endothelin-1 plasma levels in various experi- 
mental and animal models of congestive heart failure 
needs confirmation in human heart failure. 
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